FINWIRES · TerminalLIVE
FINWIRES

Veru Enters Supply Agreement With Novo Nordisk for Obesity Study; Shares Surge

By

Veru (VERU) said Thursday in a regulatory filing that it entered a clinical supply agreement with Novo Nordisk (NVO) to support its phase 2b PLATEAU study evaluating enobosarm in combination with Novo's Wegovy in older adults with obesity undergoing weight loss treatment.

Under the agreement, Novo Nordisk will provide Wegovy free of charge for the study, while Veru will sponsor and conduct the trial and share clinical study updates and insights related to obesity and weight management research, the filing shows.

Veru said it retains global development and commercialization rights to enobosarm, while Novo Nordisk received a right of first negotiation if Veru seeks to develop, commercialize or license enobosarm in combination with Novo Nordisk GLP-1 products in the future.

Shares of Veru rose 155% in Thursday trading.

Price: $5.52, Change: $+3.27, Percent Change: +145.47%

Related Articles

Wire

General Motors Rehires Over 100 Former Cruise Team Members, The Information Reports

General Motors Rehires Over 100 Former Cruise Team Members, The Information Reports

$GM
Wire

Market Chatter: Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases

Merck (MRK) said Thursday it will pay over $50 million to settle more than 200 lawsuits that blame the drugmaker's Gardasil cancer vaccine for causing autoimmune ailments in young women, Bloomberg reported, citing an emailed statement from the company.Gardasil prevents human papillomavirus infections. The lawsuits allege it can cause autoimmune conditions affecting the heart and reproductive systems in young women, according to the report.Merck didn't immediately reply to a request for comment from.Price: $119.28, Change: $+4.58, Percent Change: +3.99%

$MRK
Wire

RBC Maintains The Descartes Systems Group's Outperform Rating and US$126.00 Price Target

RBC Capital Markets maintained its outperform rating and US$126.00 price target on the shares of The Descartes Systems Group (DSG.TO, DSGX) on Thursday, after the company reported its fiscal 2027 first-quarter financial results on Wednesday.Descartes delivered another beat and raise, said RBC and added that organic growth "continued to strengthen, despite a mixed global trade environment."Strengthening organic growth validates Descartes's innovation and value proposition, said RBC. Organic growth strengthened to ~9% from 8% last quarter, despite reduced global freight shipments in the quarter, added RBC."Increased organic growth stems from adoption of Descartes's trade content, e-commerce solutions, routing & scheduling amid higher fuel costs, and freight visibility (i.e., MacroPoint)," said RBC.Descartes's customers are "increasingly utilizing more software" to help manage their operations, in light of increasing supply chain complexity and disruptions, RBC stated.Descartes is investing in the development of a new agentic AI layer on top of its core network, noted RBC.RBC believes AI agents leading to automated workflow will "increase the value and stickiness" of Descartes's network, while also creating new consumption-based revenue streams."AI agents increase visibility to the moat around Descartes's core business in an AI era," said RBC.RBC sees "compelling risk-reward, given healthy organic growth, continued margin expansion, and the likelihood of additional M&A," it said."With Descartes trading at the low end of its historical valuation range, we see attractive risk-reward on the stock," added RBC.Price: $110.10, Change: $+7.22, Percent Change: +7.02%

$DSG.TO$DSGX